RECOVER
On 23-24 November, textile industry experts Recover™, Evlox and Jeanologia will showcase their new recycled denim capsule collection, REICONICS, at Denim Première Vision in Milan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231119049088/en/
(Photo: Jeanologia)
The collection is the result of a collaborative project between the three companies, combining expertise from each specialist business to improve circularity in the denim industry, from fiber to finish.
It aims to inspire and bring value to the industry by creating truly circular products through a process that implements eco-design, transparency, process measurement, traceability, and scalability.
Made from Recover™ recycled cotton fiber and Spanish cotton, the REICONICS collection is GRS certified and is a tribute to the classic denim fabrics that have been successful in past decades.
It includes a range of premium denim fabrics developed by Evlox and a total of 14 final garments that will be exhibited at Premiere Vision Denim. Each piece in the collection displays a variety of finishes generated using technology by Jeanologia, reducing water and energy consumption, and eliminating damaging emissions and discharge.
Just one jacket in the REICONICS collection, using 32% Recover™ recycled fiber and Jeanologia finishing technology, saves up to 760 liters of water; compared to a jacket made with virgin cotton and treated with traditional finishing techniques.
Alfredo Ferre, CEO at Recover™ stated, "Recover™ is proud to be part of the REICONICS collection, a groundbreaking project that will pave the way toward a more sustainable future. Together we are offering brands a pathway to reduce their environmental impact caused by raw material production and waste.”
Francisco Ortega, Evlox R&D Director, also commented, “We are thrilled to implement new models of denim manufacturing, more circular and sustainable with the help of recognized partners such as Recover™ and Jeanologia with whom we have been collaborating for years, this capsule is another milestone in the challenge of making circular fashion accessible to everyone, without compromising the denim heritage”.
Enrique Silla, CEO at Jeanologia stated, “At Jeanologia we are proud to work with Recover™ and Evlox as partners to redefine the future of Blue jeans. REICONICS Collection creates an inflection point where technology, innovation, creativity, circularity, and sustainability are key to success. To achieve the excellent product whilst producing in a responsible and sustainable way.”
If you are interested in learning more about how to reduce the use of virgin materials in denim and reduce environmental impacts, please visit https://recoverfiber.com/newsroom/reiconics-jeanologia-evlox-recover.
ENDS
Images of the REICONICS recycled denim collection can be downloaded here.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Evlox
We are Denimakers since 1846. More than 175 years specialized in manufacturing denim, reinventing a classic, creating new solutions for the world’s most important brands. In Evlox we are passionate about our work, and for this reason we continue leading the way in the sector. With 12 million metres of Premium denim produced every year, more than 500 employees and a commercial presence in 50 countries, Evlox is today synonymous with improvement, innovation, and leadership.
About Jeanologia
Since 1994, Jeanologia’ s mission has been to create an ethical, sustainable, and eco-efficient textile industry. The company collaborates closely with brands, retailers, and their suppliers on their transformative journey. Jeanologia offers disruptive technologies, innovative software, and a new operational model. Their groundbreaking solutions, including laser technology, G2 ozone, Dancing Box, e-flow, and H2Zero, have revolutionized the textile industry, providing limitless design and garment finishing possibilities. These advancements not only reduce costs but also conserve water, energy, and chemicals, ensuring zero pollution.
Today, Jeanologia encourages all textile industry stakeholders to get behind their Mission Zero: dehydrate and detoxify the jean industry. No more water or toxic chemicals used in a single pair of jeans around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231119049088/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom